Serge Beaulieu, M.D., Ph.D., FRCPC

Serge Beaulieu

Contact

 serge.beaulieu@mcgill.ca

 

6875 Boulevard LaSalle
Montréal, QC
H4H 1R3

 Office:H-1157, Pavillon Newman

 Office phone: (514) 761-6131 x3303

 Fax: (514) 888-4062

Researcher, Douglas Research Centre
Medical Chief, Bipolar Disorders Program, Douglas Mental Health University Institute
Medical Chief, Mood, Anxiety and Impulsivity Disorders Program, Douglas Mental Health University Institute
Associate Professor, Department of Psychiatry, McGill University

Lab name: Programme des troubles bipolaires

Theme-Based Group: Stress, Anxiety, Depression, and Suicide
Division: Clinical Research

 

The Research Team of the Bipolar Disorders Program led by Serge Beaulieu, MD, PhD, FRCPC is interested in the biological and environmental factors of bipolar disorders. The aim of ongoing research projects is to identify these factors and to improve and develop better treatments for bipolar disorders. The main objective is to better understand bipolar disorders from the epidemiological, biological, chemical, psychological, social and genetic points of view. A dynamic interdisciplinary team who concentrates its efforts on carrying out various research projects, on knowledge transfer, and on providing clinical services within the Bipolar Disorders Program.

Dr Beaulieu was the recipient of the Douglas Utting Prize in 2004, which is awarded annually to one person in Canada who has contributed significantly to promoting awareness of depression and/or its research and treatment. He also, received the Teaching-Clinician Award from the Quebec Medical Association in 2009, which recognizes the exceptional contribution of a physician who also teaches at a faculty of medicine. Dr. Beaulieu is a Distinguished Fellow of the APA (American Psychiatric Association) and served as member of the Board of Councilors of the ISBD and was a member of the Scientific Council of the Canadian Psychiatric Association. He is a Board member of Revivre, a self-help community organization devoted to patients suffering from mood and anxiety disorders.